dynactin	B:C4308010
4	I:C4308010
as	O
a	O
modifier	O
of	O
chronic	O
Pseudomonas	I:C0854135
aeruginosa	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
.	O

dynactin	O
4	I:C4308010
as	O
a	O
modifier	O
of	O
chronic	B:C0854135
Pseudomonas	I:C0854135
aeruginosa	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
.	O

dynactin	O
4	I:C4308010
as	O
a	O
modifier	O
of	O
chronic	O
Pseudomonas	I:C0854135
aeruginosa	I:C0854135
infection	I:C0854135
in	O
cystic	B:C0010674
fibrosis	I:C0010674
.	O

Pseudomonas	B:C0854135
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
(	O
cystic	O
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	O
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	O
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	O
and	O
shorter	O
survival	O
.	O

Pseudomonas	O
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	B:C0010674
fibrosis	I:C0010674
(	O
cystic	O
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	O
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	O
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	O
and	O
shorter	O
survival	O
.	O

Pseudomonas	O
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
(	O
cystic	B:C0010674
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	O
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	O
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	O
and	O
shorter	O
survival	O
.	O

Pseudomonas	O
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
(	O
cystic	O
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	B:C0024115
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	O
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	O
and	O
shorter	O
survival	O
.	O

Pseudomonas	O
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
(	O
cystic	O
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	O
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	O
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	O
and	O
shorter	O
survival	O
.	O

Pseudomonas	O
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
(	O
cystic	O
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	O
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	O
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	O
and	O
shorter	O
survival	O
.	O

Pseudomonas	O
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
(	O
cystic	O
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	O
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	B:C3160731
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	O
and	O
shorter	O
survival	O
.	O

Pseudomonas	O
aeruginosa	I:C0854135
(	I:C0854135
Pa	I:C0854135
)	I:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
(	O
cystic	O
fibrosis	I:C0010674
)	O
patients	O
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	O
disease	I:C0024115
and	O
shorter	O
survival	O
,	O
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
)	O
is	O
associated	O
with	O
reduced	O
lung	O
function	O
,	O
faster	O
rate	I:C3160731
of	I:C3160731
lung	I:C3160731
decline	I:C3160731
,	O
increased	O
rates	O
of	O
exacerbations	B:C4086268
and	O
shorter	O
survival	O
.	O

By	O
using	O
exome	B:C3640077
sequencing	I:C3640077
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	O
of	O
dynactin	O
4	I:C4308010
(	O
dynactin	O
4	I:C4308010
)	O
may	O
influence	O
Pa	O
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
,	O
leading	O
to	O
worse	O
respiratory	O
disease	I:C0035204
.	O

By	O
using	O
exome	O
sequencing	I:C3640077
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	B:C0597298
of	O
dynactin	O
4	I:C4308010
(	O
dynactin	O
4	I:C4308010
)	O
may	O
influence	O
Pa	O
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
,	O
leading	O
to	O
worse	O
respiratory	O
disease	I:C0035204
.	O

By	O
using	O
exome	O
sequencing	I:C3640077
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	O
of	O
dynactin	B:C4308010
4	I:C4308010
(	O
dynactin	O
4	I:C4308010
)	O
may	O
influence	O
Pa	O
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
,	O
leading	O
to	O
worse	O
respiratory	O
disease	I:C0035204
.	O

By	O
using	O
exome	O
sequencing	I:C3640077
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	O
of	O
dynactin	O
4	I:C4308010
(	O
dynactin	B:C4308010
4	I:C4308010
)	O
may	O
influence	O
Pa	O
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
,	O
leading	O
to	O
worse	O
respiratory	O
disease	I:C0035204
.	O

By	O
using	O
exome	O
sequencing	I:C3640077
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	O
of	O
dynactin	O
4	I:C4308010
(	O
dynactin	O
4	I:C4308010
)	O
may	O
influence	O
Pa	B:C0854135
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
,	O
leading	O
to	O
worse	O
respiratory	O
disease	I:C0035204
.	O

By	O
using	O
exome	O
sequencing	I:C3640077
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	O
of	O
dynactin	O
4	I:C4308010
(	O
dynactin	O
4	I:C4308010
)	O
may	O
influence	O
Pa	O
infection	I:C0854135
in	O
cystic	B:C0010674
fibrosis	I:C0010674
,	O
leading	O
to	O
worse	O
respiratory	O
disease	I:C0035204
.	O

By	O
using	O
exome	O
sequencing	I:C3640077
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	O
of	O
dynactin	O
4	I:C4308010
(	O
dynactin	O
4	I:C4308010
)	O
may	O
influence	O
Pa	O
infection	I:C0854135
in	O
cystic	O
fibrosis	I:C0010674
,	O
leading	O
to	O
worse	O
respiratory	B:C0035204
disease	I:C0035204
.	O

The	O
purpose	O
of	O
this	O
study	B:C2603343
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	O
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	B:C4308010
4	I:C4308010
missense	O
variants	O
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	B:C0597298
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	O
on	O
Pa	B:C0854135
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	O
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	B:C0854135
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	O
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	O
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	B:C0599755
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	O
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
dynactin	O
4	I:C4308010
missense	O
variants	O
on	O
Pa	O
infection	I:C0854135
incidence	O
,	O
age	O
at	O
first	O
Pa	O
infection	I:C0854135
and	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
incidence	O
in	O
a	O
cohort	O
of	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
a	O
single	O
centre	B:C0475309
.	O

Polymerase	B:C0032520
chain	I:C0032520
reaction	I:C0032520
and	O
direct	O
sequencing	I:C3899368
were	O
used	O
to	O
screen	O
DNA	O
samples	I:C0444245
for	O
dynactin	O
4	I:C4308010
variants	O
.	O

Polymerase	O
chain	I:C0032520
reaction	I:C0032520
and	O
direct	B:C3899368
sequencing	I:C3899368
were	O
used	O
to	O
screen	O
DNA	O
samples	I:C0444245
for	O
dynactin	O
4	I:C4308010
variants	O
.	O

Polymerase	O
chain	I:C0032520
reaction	I:C0032520
and	O
direct	O
sequencing	I:C3899368
were	O
used	O
to	O
screen	O
DNA	B:C0444245
samples	I:C0444245
for	O
dynactin	O
4	I:C4308010
variants	O
.	O

Polymerase	O
chain	I:C0032520
reaction	I:C0032520
and	O
direct	O
sequencing	I:C3899368
were	O
used	O
to	O
screen	O
DNA	O
samples	I:C0444245
for	O
dynactin	B:C4308010
4	I:C4308010
variants	O
.	O

Polymerase	O
chain	I:C0032520
reaction	I:C0032520
and	O
direct	O
sequencing	I:C3899368
were	O
used	O
to	O
screen	O
DNA	O
samples	I:C0444245
for	O
dynactin	O
4	I:C4308010
variants	B:C0597298
.	O

A	O
total	O
of	O
121	O
adult	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
from	O
the	O
Cochin	O
Hospital	I:C0019994
CF	I:C0019994
centre	I:C0019994
have	O
been	O
included	O
,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	O
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	O
infection	I:C0876973
with	O
Pseudomonas	O
aeruginosa	I:C0033809
,	O
and	O
68	O
patients	O
of	O
them	O
had	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

A	O
total	O
of	O
121	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
the	O
Cochin	B:C0019994
Hospital	I:C0019994
CF	I:C0019994
centre	I:C0019994
have	O
been	O
included	O
,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	O
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	O
infection	I:C0876973
with	O
Pseudomonas	O
aeruginosa	I:C0033809
,	O
and	O
68	O
patients	O
of	O
them	O
had	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

A	O
total	O
of	O
121	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
the	O
Cochin	O
Hospital	I:C0019994
CF	I:C0019994
centre	I:C0019994
have	O
been	O
included	O
,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	B:C1413365
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	O
infection	I:C0876973
with	O
Pseudomonas	O
aeruginosa	I:C0033809
,	O
and	O
68	O
patients	O
of	O
them	O
had	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

A	O
total	O
of	O
121	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
the	O
Cochin	O
Hospital	I:C0019994
CF	I:C0019994
centre	I:C0019994
have	O
been	O
included	O
,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	O
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	B:C0876973
infection	I:C0876973
with	O
Pseudomonas	O
aeruginosa	I:C0033809
,	O
and	O
68	O
patients	O
of	O
them	O
had	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

A	O
total	O
of	O
121	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
the	O
Cochin	O
Hospital	I:C0019994
CF	I:C0019994
centre	I:C0019994
have	O
been	O
included	O
,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	O
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	O
infection	I:C0876973
with	O
Pseudomonas	B:C0033809
aeruginosa	I:C0033809
,	O
and	O
68	O
patients	O
of	O
them	O
had	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

A	O
total	O
of	O
121	O
adult	O
cystic	O
fibrosis	I:C0010674
patients	O
from	O
the	O
Cochin	O
Hospital	I:C0019994
CF	I:C0019994
centre	I:C0019994
have	O
been	O
included	O
,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	O
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	O
infection	I:C0876973
with	O
Pseudomonas	O
aeruginosa	I:C0033809
,	O
and	O
68	O
patients	O
of	O
them	O
had	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
.	O

dynactin	B:C4308010
4	I:C4308010
variants	O
were	O
identified	O
in	O
24	O
%	O
(	O
29/121	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
Pa	O
infection	I:C0854135
and	O
in	O
only	O
17	O
%	O
(	O
3/18	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
no	O
Pa	O
infection	I:C0854135
.	O

dynactin	O
4	I:C4308010
variants	B:C0597298
were	O
identified	O
in	O
24	O
%	O
(	O
29/121	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
Pa	O
infection	I:C0854135
and	O
in	O
only	O
17	O
%	O
(	O
3/18	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
no	O
Pa	O
infection	I:C0854135
.	O

dynactin	O
4	I:C4308010
variants	O
were	O
identified	O
in	O
24	O
%	O
(	O
29/121	O
)	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
with	O
Pa	O
infection	I:C0854135
and	O
in	O
only	O
17	O
%	O
(	O
3/18	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
no	O
Pa	O
infection	I:C0854135
.	O

dynactin	O
4	I:C4308010
variants	O
were	O
identified	O
in	O
24	O
%	O
(	O
29/121	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
Pa	B:C0854135
infection	I:C0854135
and	O
in	O
only	O
17	O
%	O
(	O
3/18	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
no	O
Pa	O
infection	I:C0854135
.	O

dynactin	O
4	I:C4308010
variants	O
were	O
identified	O
in	O
24	O
%	O
(	O
29/121	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
Pa	O
infection	I:C0854135
and	O
in	O
only	O
17	O
%	O
(	O
3/18	O
)	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
with	O
no	O
Pa	O
infection	I:C0854135
.	O

dynactin	O
4	I:C4308010
variants	O
were	O
identified	O
in	O
24	O
%	O
(	O
29/121	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
Pa	O
infection	I:C0854135
and	O
in	O
only	O
17	O
%	O
(	O
3/18	O
)	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
no	O
Pa	B:C0854135
infection	I:C0854135
.	O

Of	O
the	O
patients	O
with	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
,	O
29	O
%	O
(	O
20/68	O
)	O
had	O
dynactin	O
4	I:C4308010
missense	O
variants	O
vs	O
23	O
%	O
(	O
8/35	O
)	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

Of	O
the	O
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
,	O
29	O
%	O
(	O
20/68	O
)	O
had	O
dynactin	B:C4308010
4	I:C4308010
missense	O
variants	O
vs	O
23	O
%	O
(	O
8/35	O
)	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

Of	O
the	O
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
,	O
29	O
%	O
(	O
20/68	O
)	O
had	O
dynactin	O
4	I:C4308010
missense	O
variants	B:C0597298
vs	O
23	O
%	O
(	O
8/35	O
)	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
.	O

Of	O
the	O
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
,	O
29	O
%	O
(	O
20/68	O
)	O
had	O
dynactin	O
4	I:C4308010
missense	O
variants	O
vs	O
23	O
%	O
(	O
8/35	O
)	O
in	O
patients	O
without	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
.	O

Interestingly	O
,	O
p.Tyr263Cys	B:C0597298
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	B:C4308010
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	B:C0597298
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	B:C0026882
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	B:C0010674
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Interestingly	O
,	O
p.Tyr263Cys	O
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
than	O
in	O
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
(	O
4/68	O
vs	O
0/35	O
)	O
,	O
and	O
dynactin	O
4	I:C4308010
missense	O
variants	O
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
with	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	O
II	I:C0026882
mutations	I:C0026882
than	O
in	O
male	O
cystic	O
fibrosis	I:C0010674
patients	O
without	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
bearing	O
two	O
class	B:C0026882
II	I:C0026882
mutations	I:C0026882
(	O
P	O
=	O
0.06	O
)	O
.	O

Our	O
observations	O
reinforce	O
that	O
dynactin	B:C4308010
4	I:C4308010
missense	O
variants	O
,	O
especially	O
p.	O
Tyr263Cys	I:C0597298
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
in	O
male	O
cystic	O
fibrosis	I:C0010674
.	O

Our	O
observations	O
reinforce	O
that	O
dynactin	O
4	I:C4308010
missense	O
variants	B:C0597298
,	O
especially	O
p.	O
Tyr263Cys	I:C0597298
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
in	O
male	O
cystic	O
fibrosis	I:C0010674
.	O

Our	O
observations	O
reinforce	O
that	O
dynactin	O
4	I:C4308010
missense	O
variants	O
,	O
especially	O
p.	B:C0597298
Tyr263Cys	I:C0597298
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
in	O
male	O
cystic	O
fibrosis	I:C0010674
.	O

Our	O
observations	O
reinforce	O
that	O
dynactin	O
4	I:C4308010
missense	O
variants	O
,	O
especially	O
p.	O
Tyr263Cys	I:C0597298
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	B:C0699748
of	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
in	O
male	O
cystic	O
fibrosis	I:C0010674
.	O

Our	O
observations	O
reinforce	O
that	O
dynactin	O
4	I:C4308010
missense	O
variants	O
,	O
especially	O
p.	O
Tyr263Cys	I:C0597298
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
chronic	B:C0854135
Pa	I:C0854135
infection	I:C0854135
in	O
male	O
cystic	O
fibrosis	I:C0010674
.	O

Our	O
observations	O
reinforce	O
that	O
dynactin	O
4	I:C4308010
missense	O
variants	O
,	O
especially	O
p.	O
Tyr263Cys	I:C0597298
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
Pa	I:C0854135
infection	I:C0854135
in	O
male	O
cystic	B:C0010674
fibrosis	I:C0010674
.	O

